



Press-release

Moscow, 09.11.2020

Skolkovo and Servier support Russian startups in the field of oncology and autoimmune diseases

Biomedical cluster of Skolkovo Foundation and pharmaceutical company Servier have announced the start of a scouting mission to identify and to support the startups in the field of oncology and autoimmune diseases. Project applications could be submitted till December 1st, 2020

The project will be the first step in the implementation of the Memorandum of Cooperation, which was signed by Arkady Dvorkovich, Chairman of the Skolkovo Foundation, and Jérôme Gavet, Managing Director for Servier Russia and EAEU.

Arkady Dvorkovich, Chairman of the Skolkovo Foundation:

“We are glad to initiate scouting project in cooperation with Servier. We have more than 600 residents in our Biomedical cluster, and partner with the majority of scientific and research institutes across Russia. This gives to our industrial partners a unique opportunity to access early-stage projects though scouting missions. During this new pandemic reality, we are supporting our partners’ business development aims”

Dr. Claude Bertrand, Executive Vice-President Research & Development at Servier:

«Our partnerships philosophy is about accessing innovative new therapeutic solutions to meet patient needs. Starting a collaboration with Skolkovo Foundation, a leading innovation center in Russia, is definitely inspiring».

Jérôme Gavet, Managing Director for Russia and EAEU at Servier:

“This project will make a significant contribution to the fight against cancer and immuno-inflammatory diseases, provide an additional opportunity for the local projects to enter the international market and, thereby, increase the availability of innovative therapeutic solutions for patients around the world”

Research teams and biotech startups that are interested to participate in the scouting mission should propose therapeutic compounds in oncology or/and immune-inflammatory fields.

The startups should be open to a partnership (flexible ad hoc structures) and be ready provide a clear description of the therapeutic opportunity, detailing: target and therapeutic pathways involved, the mode of action (with in vitro and/or in vivo data), therapeutic modality, as well as development stage and IP strategy.

Successful applicants will be considered for further evaluation by Servier Group R&D department, with a potential for partnership (through a due-diligence process).

Project applications could be submitted till December 1st at biotech.scouting@sk.ru.

For more information visit the website: biotechscouting.sk.ru

Biomedical cluster of Skolkovo Foundation is actively working with corporate partners in external innovations development. The cluster possess deep biotech understanding and innovative landscape knowledge, that allows its corporate and industrial partners to get quick access to the most promising initiatives in drug development and other directions (digital medicine, cell therapy, medtech).

Becoming a key player in oncology and therapy of immune-inflammatory disease is part of Servier's long-term strategy. Servier strives to bring innovative therapeutic solutions to patients suffering from these often highly debilitating pathologies. Its research in auto-immune diseases focuses on lupus, Gougerot-Sjögren syndrome and scleroderma, for which a huge unmet medical need exists. Given the high demand of therapeutic solutions in oncology, Servier has decided to make the fight against cancer a priority: by 2021, oncology should account for half of its overall R&D budget. Servier's oncology R&D programs explore two major areas: apoptosis and immuno-oncology. This goal will be reached by establishing partnerships all over the world in order to accelerate the marketing of innovative drugs with high added value for patients.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

More information: www.servier.com

Servier has been operating in Russia for almost 30 years remaining one of the leading pharmaceutical companies. In 1999 an R&D center was established in Moscow. In 2007, a full-cycle pharmaceutical plant Servier RUS was launched in Moscow. Servier RUS plant meets all international requirements and good manufacturing practice (GMP) standards and producing a wide range of modern original medicines for patients in Russia and other EAEU countries. Today more than 90% of medications of Servier Russia portfolio are produced at Servier RUS on a full cycle.

More information: www.servier.ru

Press-contact:

Yana Kotukhova, External Affairs Director Servier Russia and EAEU

E-mail: Yana.KOTUKHOVA@servier.com

About Skolkovo Foundation

Non-profit organization founded in 2010 and functions as the administrator of the Skolkovo Innovation Center. The goal of the Foundation is to support technological entrepreneurship in Russia and the commercialization of the results of research activities.

The number of Skolkovo residents has already reached nearly 2,500. The Foundation provides them with an array of services that are necessary to roll out developments onto the Russian and international markets. Resident status gives a company tax and customs privileges. In 2019, residents' revenue comprised over 100 billion rubles, and the amount of investment they raised amounted to 13 billion rubles. Since 2019, legislation has allowed any organization conducting research activities in Russia to access the services and benefits of the Skolkovo Innovation Center. Located on the Skolkovo Innovation Center territory is the Skolkovo Institute of Science and Technology (Skoltech), which is in the world's top-100 young universities according to the Nature Index. The Innovation Center infrastructure comprises, among other things, the research centers of industrial partners and the largest Technopark in Europe. In 2019, three new partner R&D centers, which belong to Sibur, TMK, and Tatneft, opened at the innovation center. A total of 750,000 square meters of residential buildings, research and educational centers have been put into operation on Skolkovo territory, and extrabudgetary investment in infrastructure exceeded 100 billion rubles.

Website: www.sk.ru.
Telegram: [@oi_press](https://www.instagram.com/oi_press)

Press-contact:
Alexandra Barshevskaya, Press-secretary
Skolkovo Foundation,
E-mail: ab@sk.ru